Table 5

Change from baseline in category rating scales for amount of symptoms and multiple sclerosis specific questionnaires

VariableCannabis extract (N=143)Placebo (N=134)
CRS* Muscle stiffness−1.8±2.6−0.7±2.4
Body pain−1.2±2.6−0.3±2.4
Muscle spasms−1.5±2.7−0.7±2.4
Quality of sleep−1.4±3.1−0.9±2.6
MSSS-88§ Muscle stiffness−5.0±8.5−1.3±7.9
Pain and discomfort−3.0±6.4−1.6±6.2
Muscle spasms−5.2±9.9−2.1±9.2
Effect of spasticity on activities of daily living−1.3±8.0−1.6±8.2
Effect of spasticity on ability to walk−3.0±5.7−1.4±4.2
Effect of spasticity on body movement−3.9±7.7−1.8±7.9
Effect of spasticity on feelings−2.1±8.9−1.8±9.1
Effect of spasticity on social functioning−1.2±6.2−1.0±5.6
MSIS-29§ Physical impact−10.1±23.2−4.2±18.5
Psychological impact−6.3±23.7−3.8±22.8
MSWS-12 Total score−9.0±17.6−1.7±12.4
  • Scores were transformed to a 0–100 scale using the formula 100× (observed score−minimum score)/(maximum score−minimum score).

  • * Assessed by an 11 point numerical Likert scale (0=no symptom expression, …, 10=extreme symptom expression).

  • Difference between cannabis extract and placebo: p<0.025 (one sided) (Lehmann's aligned rank test; factors for muscle stiffness and the MSSS-88—treatment, ambulatory status, spasticity medication; factors for body pain—treatment, analgesic medication, CRS baseline status; factors for muscle spasms and quality of sleep—treatment, spasticity medication, CRS baseline status; factors for MSIS-29—treatment, ambulatory status; factor for MSWS-12—treatment).

  • § Possible answers: 1, not at all bothered/limited; 2, a little bothered/limited; 3, moderately bothered/limited; 4, extremely bothered/limited.

  • Possible answers: 1, not at all; 2, a little; 3, moderately; 4, quite a bit; 5, extremely.

  • CRS, category rating scale; MSIS-29, Multiple Sclerosis Impact Scale; MSSS-88, Multiple Sclerosis Spasticity Scale; MSWS-12, Multiple Sclerosis Walking Scale; N, number of patients in specified treatment group; mean, mean change from baseline.